Researchers plan to initiate a phase 2 trial of the vaccine, which will enroll up to 25 patients with metastatic chordoma.
Cancer Therapy Advisor has updated its treatment regimen chart for the treatment of bone cancer.
Researchers have constructed baseline event-free survival outcomes as a comparison for future trials, so that time to disease progression can be used as an end point.
Denosumab has robust clinical efficacy in the treatment of patients with giant cell tumor of bone (GCTB).
Pacritinib induced significant and sustained spleen volume reduction (SVR) and symptom control in patients with myelofibrosis.
Survival rate for mesenchymal chondrosarcoma, a rare form of cancer, is not as dismal as previously reported.
Researchers discovered that the bone tumor tissue has higher concentrations of trace elements.
Patients with osteosarcoma had more metastasis and higher recurrence rates if they received manipulation therapy.
New MRI-guided focused ultrasound reduces pain from bone metastases.
Zoledronate does not improve survival rates among women with chemoresistant breast cancer.
Xgeva (denosumab; Amgen) has been approved for the treatment of unresectable giant cell tumor of the bone (GCTB) in adult and adolescent patients.
Imatinib is prolongs PFS but not OS compared to placebo among patients with imatinib- or sunitinib-refractory advanced GIST, according to data presented at ASCO 2013.
Celgene announced that the FDA has approved Pomalyst (pomalidomide) for the treatment of patients with relapsed and/or refractory multiple myeloma.
In synovial sarcoma, metastasis development is linked to chromosome complexity.
Development of metastasis in synovial sarcoma is strongly associated with chromosome complexity, which helps explain why adults more frequently have metastasis than children: the adult genome is more frequently rearranged.
Outpatient autologous stem cell transplantation might be a safe alternative to high-dose chemotherapy with ASCT for patients with multiple myeloma, but most patients (78%) are hospitalized for febrile neutropenia within 100 days.
Bisphosphanates are associated with fewer and later-onset skeletal-related events and better pain control among patients with bone metastasis from lung cancer.
Denosumab significantly reduced or eliminated RANK-positive tumor giant cells in patients with giant-cell tumor of bone (GCTB).
Patients diagnosed with Ewing sarcoma after age 39 years have significantly higher risks of extra-skeletal tumors and metastatic disease, and poorer 5-year survival rates, than patients diagnosed at younger ages.
Rate of recurrence is significantly lower with marginal excision versus curettage alone.